Table 1.
Mutant GFAP as a percent of total GFAP in R79C, R416W, and R239H Alexander disease patients
Total GFAP is the sum of the amount of patient GFAP and 15N standard GFAP analyzed. The control peptides for trypsin digestion were FADLTDAAAR (1), LADVYQAELR (2), ALAAELNQLR (3), and LLEGEENR (4). The control peptides for chymotrypsin digestion were ARQQVHVEL (1), RQEADEATL (2), and IEKVRF (3). IEKVRF is also present in desmin and peripherin, but these proteins are not expected to be present in the brain at significant levels compared to GFAP. Were significant levels indeed present, their inclusion would lead to overestimation of the amount of WT GFAP present and, thus, underestimation of the percent mutant GFAP. With inclusion of IEKVRF, the calculated percent mutant GFAP was actually slightly higher than that obtained if it were excluded (29% versus 27%). ND, not detected in the patient sample, the 15N standard, or both; Amt, amount; Dig, digestion; MUT, mutant.
Amt 15N Std |
Total GFAP |
Dig time |
% Mutant |
Peptide Ratios (Patient/15N Std) Intact GFAP Band |
Peptide Ratios (Patient/15N-Std) Degraded GFAP Band |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ng | ng | h | Intact | Degraded | Diagnostic | Controls | Diagnostic | Controls | ||||||
R79C patient, trypsin digestion | WT | 1 | 2 | 3 | 4 | WT | 1 | 2 | 3 | 4 | ||||
50 | 120 | 40 | 21% | 25% | 0.76 | 0.99 | 1.00 | 0.96 | 0.88 | 1.41 | 1.90 | 2.09 | 1.83 | 1.72 |
100 | 170 | 18 | 22% | ND | 0.46 | 0.63 | 0.59 | 0.53 | 0.59 | ND | ND | ND | 0.95 | ND |
100 | 170 | 40 | 21% | 23% | 0.48 | 0.65 | 0.61 | 0.63 | 0.56 | 0.85 | 1.15 | 1.18 | 1.07 | 0.99 |
150 | 220 | 40 | 19% | 22% | 0.38 | 0.51 | 0.47 | 0.47 | 0.42 | 0.57 | 0.77 | 0.78 | 0.71 | 0.66 |
Average ± SD | 21% ± 1% | 23% ± 2% | ||||||||||||
R416W patient, trypsin digestion | MUT | 1 | 2 | 3 | 4 | MUT | 1 | 2 | 3 | 4 | ||||
13.5 | 90.5 | 40 | 45% | 19% | 2.81 | 6.13 | 6.45 | 5.89 | 6.70 | 0.25 | 1.35 | 1.53 | 1.32 | 0.96 |
36 | 113 | 18 | 47% | 20% | 1.11 | 2.34 | 2.55 | 2.28 | 2.32 | 0.11 | 0.54 | 0.66 | 0.56 | 0.35 |
36 | 113 | 40 | 45% | 22% | 1.04 | 2.27 | 2.45 | 2.16 | 2.43 | 0.11 | 0.55 | 0.56 | 0.52 | 0.38 |
58.5 | 135.5 | 40 | 45% | 22% | 0.67 | 1.53 | 1.54 | 1.43 | 1.41 | 0.06 | 0.32 | 0.34 | 0.30 | 0.20 |
Average ± SD | 46% ± 1% | 21% ± 2% | ||||||||||||
R239H patient, chymotrypsin digestion | MUT | 1 | 2 | 3 | MUT | 1 | 2 | 3 | ||||||
10 | 190 | 72 | 30% | ND | 10.43 | ND | 34.99 | ND | ND | ND | ND | ND | ||
50 | 230 | 48 | 33% | ND | 1.97 | ND | 7.17 | 4.71 | ND | ND | 7.07 | ND | ||
50 | 230 | 72 | 22% | ND | 1.55 | ND | 6.56 | 7.28 | ND | ND | 13.97 | ND | ||
100 | 280 | 72 | 33% | ND | 0.88 | 3.21 | 2.91 | 2.00 | ND | ND | 4.30 | ND | ||
Average ± SD | 29% ± 5% |